T. Vink

发表

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells.

P. Parren, T. Schneider-Merck, M. Peipp, 2008, Blood.

Crosstalk between Human IgG Isotypes and Murine Effector Cells

P. Parren, S. Verploegen, J. Leusen, 2012, The Journal of Immunology.

A simple, robust and highly efficient transient expression system for producing antibodies.

T. Vink, R. D. de Jong, M. Oudshoorn-Dickmann, 2014, Methods.

Epidermal Growth Factor Receptor (EGFR) Antibody-Induced Antibody-Dependent Cellular Cytotoxicity Plays a Prominent Role in Inhibiting Tumorigenesis, Even of Tumor Cells Insensitive to EGFR Signaling Inhibition

P. Parren, S. Verploegen, J. J. Lammerts van Bueren, 2011, The Journal of Immunology.

InhibitionCells Insensitive to EGFR Signaling in Inhibiting Tumorigenesis, Even of Tumor Cellular Cytotoxicity Plays a Prominent Role Antibody-Induced Antibody-Dependent Epidermal Growth Factor Receptor (EGFR)

P. Parren, S. Verploegen, W. Bleeker, 2011 .

Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG

P. Parren, A. Heck, A. Labrijn, 2013, mAbs.

Rapid production of recombinant human IgG With improved ADCC effector function in a transient expression system

P. Parren, P. V. van Berkel, T. Vink, 2010, Biotechnology and bioengineering.

and PMN effector cells Antibody fucosylation differentially impacts cytotoxicity mediated by NK

P. Parren, T. Schneider-Merck, M. Peipp, 2009 .

N‐linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG

Tom Vink, P. Parren, P. V. van Berkel, 2009, Biotechnology progress.

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

Kenneth C. Anderson, Paul W. H. I. Parren, Jerry W. Slootstra, 2011, The Journal of Immunology.

Multiple substitutions in the von Willebrand factor gene that mimic the pseudogene sequence.

P. Reitsma, J. Sixma, J. Eikenboom, 1994, Proceedings of the National Academy of Sciences of the United States of America.

A3 Domain Is Essential for Interaction of von Willebrand Factor with Collagen Type III

J. Sixma, P. D. de Groot, M. Schiphorst, 1996, Thrombosis and Haemostasis.

Species-Specific Determinants in the IgG CH3 Domain Enable Fab-Arm Exchange by Affecting the Noncovalent CH3–CH3 Interaction Strength

P. Parren, I. Lasters, A. Heck, 2011, The Journal of Immunology.

Functional studies on platelet adhesion with recombinant von Willebrand factor type 2B mutants R543Q and R543W under conditions of flow.

J. Sixma, P. D. de Groot, M. Schiphorst, 1997, Blood.

Efficient payload delivery by a bispecific antibody targeting HER2 and CD63

P. Parren, R. Wubbolts, T. Vink, 2016 .

The 33-kDa Platelet α-granule Membrane Protein (GMP-33) Is an N-terminal Proteolytic Fragment of Thrombospondin

J. Sixma, H. Nieuwenhuis, T. Vink, 2001, Thrombosis and Haemostasis.

Role of the glycoprotein Ib-binding A1 repeat and the RGD sequence in platelet adhesion to human recombinant von Willebrand factor.

J. Sixma, P. D. de Groot, M. Schiphorst, 1995, Blood.

Murine Effector Cells Crosstalk between Human IgG Isotypes and

S. Verploegen, J. Leusen, W. Bleeker, 2022 .

Hematological Tumors of Multiple Myeloma and Other CD38 Monoclonal Antibody, Induces Killing Daratumumab, a Novel Therapeutic Human

Lukas, P. Parren, M. Peipp, 2010 .

Leu 697-->Val mutation in mature von Willebrand factor is responsible for type IIB von Willebrand disease.

T. Vink, C. Mazurier, C. Gaucher, 1994, Blood.

Mutants of the elongation factor EF‐Tu, a new class of nonsense suppressors.

L. Bosch, B. Kraal, E. Vijgenboom, 1985, The EMBO journal.

Drug target discovery by pharmacogenetics: mutations in the melanocortin system and eating disorders

R. Adan, T. Vink, 2001, European Neuropsychopharmacology.

The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD201

P. Parren, M. Glennie, J. Teeling, 2006, The Journal of Immunology.

Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C.

J. Sixma, M. Schiphorst, T. Vink, 1996, Blood.

Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange

P. Parren, L. Aarden, M. D. de Baets, 2007, Science.

Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys

P. Parren, B. '. ’t Hart, A. Labrijn, 2017, Scientific Reports.

von Willebrand Factor without the A2 Domain Is Resistant to Proteolysis

J. Sixma, P. D. de Groot, M. Schiphorst, 1997, Thrombosis and Haemostasis.

Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen.

P. V. van Genderen, J. Sixma, T. Vink, 1994, Blood.

Tissue Factor Expression on Mesothelial Cells is Induced during in vitro Culture – Manipulation of Culture Conditions Creates Perspectives for Mesothelial Cells as a Source for Cell Seeding Procedures on Vascular Grafts

J. Sixma, H. Verhagen, B. Eikelboom, 1995, Thrombosis and Haemostasis.

Association between an agouti-related protein gene polymorphism and anorexia nervosa

H Remschmidt, H. Engeland, R. Adan, 2001, Molecular Psychiatry.

Binding of von Willebrand Factor to Collagen Type III: Role of Specific Amino Acids in the Collagen Binding Domain of vWF and Effects of Neighboring Domains

J J Sixma, J. Sixma, P. D. de Groot, 2000, Thrombosis and Haemostasis.

Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63

Tom Vink, P. Parren, R. Wubbolts, 2016, Molecular Cancer Therapeutics.

Recombinant vWF Type 2A Mutants R834Q and R834W Show a Defect in Mediating Platelet Adhesion to Collagen, Independent of Enhanced Sensitivity to a Plasma Protease

J. Sixma, P. D. de Groot, M. Schiphorst, 1999, Thrombosis and Haemostasis.

Platelet thrombus formation on collagen at high shear rates is mediated by von Willebrand factor-glycoprotein Ib interaction and inhibited by von Willebrand factor-glycoprotein IIb/IIIa interaction.

J. Sixma, P. D. de Groot, M. Schiphorst, 2000, Arteriosclerosis, thrombosis, and vascular biology.

HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design

P. Parren, M. Peipp, T. Riedl, 2014, mAbs.

Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells

P. Parren, T. Vink, J. V. D. van de Winkel, 2016, The Journal of Immunology.

Crosstalk between Human IgG Isotypes and

Antonio Ortiz, Tom Vink, Wim K. Bleeker, 2012 .

CH3 - Affecting the Noncovalent CH3 CH3 Domain Enable Fab-Arm Exchange by Species-Specific Determinants in the IgG

P. Parren, I. Lasters, A. Heck, 2011 .

Daratumumab, a Novel Potent Human Anti-CD38 Monoclonal Antibody, Induces Significant Killing of Human Multiple Myeloma Cells: Therapeutic Implication.

P. Parren, N. Munshi, P. Richardson, 2009 .

Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies.

P. Parren, T. Vink, J. V. D. van de Winkel, 2008, Blood.

II CD20 monoclonal antibodies Complement activation impacts B-cell depletion by both type I and type

P. Parren, T. Vink, F. Beurskens, 2008 .

This information is current as Murine Effector Cells Crosstalk between Human IgG Isotypes and and

P. Parren, S. Verploegen, J. Leusen, 2012 .

Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys

P. Parren, B. '. ’t Hart, A. Labrijn, 2017, Scientific Reports.

IgG 4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys

T. Vink, Margreet, 2017 .

Anticorps igg4 stables

P. Parren, T. Vink, R. Aalberse, 2008 .